Scope
EAU separates testicular germ-cell tumour care by seminoma versus non-seminoma, stage, post-orchidectomy markers and IGCCCG prognosis. Cure is common, so decisions must also account for fertility, treatment toxicity and whether reliable surveillance is feasible. Persistently raised markers and post-chemotherapy residual masses require specific pathways rather than management by imaging stage alone.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Establish histology and stage while protecting fertility
- Discuss sperm banking before treatment. Examine the testes, breasts and relevant lymph-node regions, and obtain bilateral testicular ultrasound whenever cancer is suspected. Normal tumour markers or a very small lesion do not reliably exclude malignancy. [1]
- Measure AFP, hCG and LDH before and after orchidectomy and interpret the decline using marker half-lives. A significant AFP increase in apparent seminoma raises concern for a non-seminomatous component; normalized markers after surgery still do not exclude metastases. [1]
- Use inguinal orchidectomy and pathological examination to establish the diagnosis and local extent; avoid a scrotal approach when malignancy is suspected. Life-threatening extensive metastases are an exception in which chemotherapy may start before orchidectomy. [1]
- Stage confirmed cancer with contrast CT of chest, abdomen and pelvis; use abdominal/pelvic MRI when iodine allergy or other limitations prevent CT. Brain MRI, or contrast CT if unavailable, is indicated for multiple lung metastases, high hCG, poor IGCCCG prognosis or neurological symptoms. Do not use PET-CT or bone scanning for initial staging. [1]
- Discuss testis-sparing surgery with frozen-section assessment for suitable masses highly likely to be benign. This is not the routine alternative for a confirmed germ-cell cancer. Discuss contralateral biopsy when risk of in-situ neoplasia is high, and offer a testicular prosthesis after unilateral or bilateral orchidectomy. [1]
Offer surveillance or adjuvant care according to histology
- For clinical stage I seminoma, explain recurrence risk and acute and long-term harms of all options. Surveillance is preferred when resources and adherence allow; do not give adjuvant treatment to patients at very low recurrence risk without risk factors. [1]
- If stage I seminoma adjuvant chemotherapy is chosen, use a single carboplatin course targeting AUC 7 under an oncology protocol. Do not routinely give adjuvant radiotherapy; reserve it for highly selected patients. AUC is an exposure target, not a fixed milligram dose. [1]
- For stage I non-seminoma, discuss surveillance, adjuvant chemotherapy and the limited role of retroperitoneal lymph-node dissection. Use lymphovascular invasion in risk-adapted discussion. In low-risk stage IA without vascular invasion, offer surveillance if feasible, or one BEP course if surveillance is unsuitable or declined. [1]
- With vascular invasion in stage I non-seminoma, offer either one course of BEP or surveillance after discussing trade-offs. Offer surveillance when adjuvant chemotherapy is declined. Nerve-sparing retroperitoneal dissection is reserved for highly selected patients unable to receive adjuvant chemotherapy and unwilling to accept surveillance. [1]
- If AFP or hCG rises or fails to normalize after orchidectomy, check the contralateral testis and follow markers weekly. After excluding a contralateral tumour, unequivocally elevated markers indicate micrometastatic disease requiring treatment by IGCCCG prognosis. Stable slight elevations may initially be monitored; progression changes that decision. [1]
Preserve marker status and prognosis when choosing treatment
- For seminoma with equivocal retroperitoneal nodes below 2 cm and normal markers, reassess after six to eight weeks. Start metastatic treatment only when biopsy, nodal progression or marker rise makes metastatic disease unequivocal. [1]
- For stage IIA/B seminoma, offer cisplatin-based chemotherapy by prognosis or alternatively radiotherapy after discussing long-term toxicity. De-escalation approaches, including retroperitoneal dissection, should be considered only in high-volume specialist centres; these recommendations are weak. [1]
- For small-volume marker-negative stage IIA non-seminoma below 2 cm, repeat staging after six weeks before committing to further treatment. For established marker-negative stage IIA disease, nerve-sparing retroperitoneal dissection by an experienced specialist-centre surgeon is the recommended initial approach; these are weak recommendations. [1]
- For stage IIA/B non-seminoma with elevated markers, use metastatic IGCCCG risk-group treatment with three or four BEP cycles. BEP means bleomycin, etoposide and cisplatin. Primary retroperitoneal dissection is not recommended for marker-positive disease outside a specific referral-centre study. [1]
- For seminoma stage IIC or higher, use primary cisplatin-based chemotherapy according to prognosis: three BEP cycles for good prognosis and four for intermediate prognosis. Carboplatin-based metastatic regimens are not equivalent to the cisplatin approach. [1]
- For intermediate-prognosis metastatic non-seminoma, use four BEP cycles. In poor-prognosis disease, assess marker decline after the first chemotherapy cycle: favourable decline supports four BEP cycles, whereas unfavourable decline warrants consideration of treatment intensification at specialist level. [1]
- During first-line chemotherapy for metastatic germ-cell tumours, balance the individual benefit and bleeding risk of thromboprophylaxis. Avoid central venous-access devices where possible. These are weak recommendations and do not mandate anticoagulation for every patient. [1]
Manage residual masses differently in seminoma and non-seminoma
- After chemotherapy for seminoma, initially monitor a residual mass with imaging and markers. For a mass above 3 cm, consider FDG-PET no earlier than two months after chemotherapy. A single positive PET result alone must not determine further treatment. [1]
- For non-seminoma after chemotherapy, resect visible residual masses above 1 cm when markers are normal or normalizing. FDG-PET does not reliably characterize these residual masses. Management of smaller residuals needs individual discussion; after salvage chemotherapy even smaller residuals can require surgery. [1]
Plan surveillance and survivorship explicitly
- Select follow-up by histology, initial stage and treatment response. The minimum surveillance schedules do not apply unchanged to poor-prognosis disease or patients without complete remission; these patients require an individual specialist-centre plan. [1]
- Do not use FDG-PET routinely during surveillance. Correlate raised AFP, hCG or LDH with imaging and repeat measurements because false positives occur. After five years, follow-up increasingly addresses late toxicity; new relapse symptoms still warrant prompt imaging and markers. [1]
- Screen and treat hypertension, dyslipidaemia and testosterone deficiency during follow-up, promote a healthy lifestyle and provide a survivorship plan covering late effects, recurrence risk and ongoing cancer follow-up. [1]
Limitations and use
- This summary covers adult germ-cell tumour diagnosis, major stage-based decisions and selected follow-up principles. It does not reproduce complete TNM/IGCCCG classification, chemotherapy doses or supportive care, detailed surveillance tables, salvage regimens, brain-metastasis treatment or rare non-germ-cell tumours.
- BEP cycle counts are not a complete prescription. Bleomycin eligibility, organ function, fertility and treatment toxicity require an oncology protocol; substitute regimens and intensification need specialist selection.
- Marker-negative and marker-positive pathways, seminoma and non-seminoma, and post-first-line versus post-salvage residual masses must remain distinct. Surveillance depends on reliable attendance and access to the specified investigations.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Testicular cancer
Selected recommendation material consulted
Publication details
- Issuing organisation
- EAU
- Resource type
- Clinical guideline · House clinical summary
- Source setting
- Europe
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.